Cambrex is an innovative life sciences company with a refreshingly human approach to the way we do business. Our pharmaceutical products, technologies and expertise accelerate your small molecule therapeutics into the market.Learn more
Cambrex today announced it has entered into a definitive agreement to acquire Halo Pharma (Halo), a leading dosage form Contract Development and Manufacturing Organization (CDMO), majority owned by funds managed by the private investment firm SK Capital Partners, for approximately $425 million. With the acquisition of Halo, Cambrex will enter the large and growing finished dosage form CDMO market.Learn more
Active Pharmaceutical Ingredients and dynamic people come together to create the Cambrex effect. Watch our video to learn how we can accelerate your small molecule therapeutics into the market.
Cambrex is a leading global supplier of more than 90 generic APIs.
With API R&D and cGMP facilities in the USA and Europe, Cambrex can support your project in regulated, emerging and developing markets. We are in your neighbourhood, wherever you are.See our facilities